News

 

NEWS

Naked Biome Entering Clinical Trials to Target Propionibacterium Acnes

Naked Biome Entering Clinical Trials to Target Propionibacterium Acnes Naked Biome is developing a probiotic therapy for acne. Instead of killing P. acnes, the QB3@953 startup, would have patients flood their faces with live, healthy strains of bacterium, ensuring the good bacterial will outcompete the bad. Full Scientific American Article

Read more

Pionyr Immunotherapeutics Completes $62M Series B Financing to Advance Antibody-based Therapeutics Targeting the Tumor Microenvironment

Pionyr Immunotherapeutics Completes $62M Series B Financing to Advance Antibody-based Therapeutics Targeting the Tumor Microenvironment Max Krummel, PhD, Pionyr Co-Founder and Robert E. Smith Endowed Chair in Experimental Pathology, UCSF Pionyr Immunotherapeutics, a company at QB3@953, is developing antibody therapeutics that increase the body’s antitumor immunity by rebalancing the myeloid infiltrate in the tumor microenvironment, announced the closing of a […]

Read more

We Welcome Engine Biosciences

Engine Biosciences is a venture-backed technology company integrating experimental biology and data science to map and decipher complex biological networks for more effective and efficient drug discovery. Engine’s technologies culminate from several years of research by our scientific founders who include faculty members of MIT, Harvard, Mayo Clinic, and UCSD, and our leadership team is applying our previous successful company […]

Read more

Asilomar Bio and Koch Biological Solutions Agree to Exclusive Commercial License of Leading Yield Enhancement Technology

Asilomar Bio and Koch Biological Solutions Agree to Exclusive Commercial License of Leading Yield Enhancement Technology QB3@953 startup, Asilomar has developed a small molecule to improve plant stress response. Koch Biological Solutions, LLC has secured exclusive global rights to commercialize and market products containing Asilomar Bio’s flagship yield enhancement technology for foliar, in-furrow, and other modes of application on a […]

Read more

We Welcome Scribe Biosciences

Scribe Biosciences is developing the next generation of high throughput single cell analysis tools for clinical and research applications. The company is based on Printed Droplet Microfluidics (PDM), a technology spun out of the Abate and Gartner labs at UCSF to enable the flexible and programmable handling of single cells with unsurpassed control. Scribe is currently being contracted by DARPA […]

Read more

We Welcome Mitokinin

Mitokinin is developing a novel class of kinase-targeted neo-substrates for the treatment of neurodegenerative and mitochondrial diseases.

Read more

Logicink announces first product to market: Logicink UV

  On October 19, at Breakout Lab’s Unboxing event, LogicInk, a pioneer in programmable materials, announced its first product to market: LogicInk UV, a wearable that resembles a temporary tattoo and monitors your UV exposure, signaling when it is time to take action to prevent skin damage. The company’s first product, LogicInk UV, targets people concerned about radiation from the sun that can […]

Read more

We Welcome Prellis Biologics

  Prellis Biologics is developing technology to build transplantable human organs and tissues. Their aim is to address the organ shortage and provide human tissues to streamline the development of therapeutics. The first transplantable human tissues Prellis Biologics is working to develop are the insulin secreting units of the pancreas, Islets of Langerhans. A renewable, safe source of Islets of […]

Read more

New partnership with TetraScience

QB3@953 is happy to announce an exciting new partnership with TetraScience, the leading Internet of Things for science company. QB3@953’s goal is to be the most efficient and “lean” lab on the planet, and TetraScience’s ability to connect existing instruments and lab systems to a single online dashboard, will help us reach this goal. We are also working on new projects […]

Read more

Siolta Therapeutics wins the Bugs, Drugs, & Beyond QuickFire Challenge

  Johnson & Johnson Innovation, JLABS and the Janssen Human Microbiome Institute (JHMI) launched the second Bugs, Drugs, & Beyond QuickFire Challenge. Taking place in both San Francisco and Cambridge, the Challenge awarded winners with a customized package of support from the JHMI and JLABS, including coaching and $75,000 in funding or entrance to the South San Francisco or Boston JLABS sites, […]

Read more
Page 3 of 1112345...10...Last »

Upcoming Event

Address

953 Indiana St., San Francisco, CA 94107
Tel: (415)-347-8287
Map

Sign-Up for our Newsletter